Aurobindo Pharma Limited (AUROPHARMA.BO) stock analysis

In our weekly check, Aurobindo Pharma Limited is graded B (A to F). Of 25 checks on debt, profit, cash flow and trend: 20 pass, warnings: 1, red flags: 4.

About Aurobindo Pharma Limited

Aurobindo Pharma Limited is a Healthcare company (Drug Manufacturers - Specialty & Generic) based in India, listed on BSE as AUROPHARMA.BO.

What our checks show for AUROPHARMA.BO

Red flags

• The gross margin fell by 10.5 points, to 44.9%: costs are rising faster than prices.
• The stock has fallen as much as 87% from a peak. Would you have held through that?
• Thinly traded (about 41 thousand shares a day): buying and selling can move the price.
• Return on capital (ROCE) is zero or negative: the business does not earn on the money put into it.

Warning signs

• The net margin fell by 0.6 points over 5 years, to 10.6%: the company keeps less of each sale as profit.

Strengths

• Debt is low: 0x equity.
• Operating profit covers interest 13.6 times over.
• Operating cash flow is 1.48x net profit: the profit arrives as real cash.
• Analysts expect earnings per share to grow about 19.1% a year over the next years.
• Earnings per share grew 24.8% a year over the last 3 years.
• Net profit grew 24.4% a year over the last 3 years.

Next earnings report: 2026-11-04

Similar companies

LUPIN.NS · MANKIND.NS · CIPLA.BO · DRREDDY.NS · ZYDUSLIFE.NS · LAURUSLABS.NS

Questions

What grade does Aurobindo Pharma Limited (AUROPHARMA.BO) have?

In our weekly check, Aurobindo Pharma Limited is graded B (A to F). Of 25 checks on debt, profit, cash flow and trend: 20 pass, warnings: 1, red flags: 4. The grade is a risk check, not a buy or sell recommendation.

What are the main risks of AUROPHARMA.BO stock?

This week's biggest flags for Aurobindo Pharma Limited: Gross margin falling, Deep past fall, Thinly traded. In total 5 of 25 checks show a warning or a red flag.

What does Aurobindo Pharma Limited do?

Aurobindo Pharma Limited is a Healthcare company (Drug Manufacturers - Specialty & Generic) based in India, listed on BSE as AUROPHARMA.BO.

When does Aurobindo Pharma Limited report earnings next?

The next earnings report is expected on 2026-11-04. We re-run the checks every week, so the grade can change after it.

The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.

Updated 2026-10-31

Open the full analysis